What SJJ Solutions does

SJJ Solutions B.V. is a Dutch medical device company headquartered in The Hague, Netherlands, founded in 2012, that designs, manufactures, and sells the Zero Residual™ product line — an integrated system of silicone oil-free syringes, needles, bubble adapters, luer lock caps, and silicone oil-free filter needles for small-volume drug delivery. The flagship Zero Residual™ 0.2ml silicone oil-free syringe, which received CE MDR approval in December 2022 as the world's first such device specifically tailored for intravitreal injections, targets ophthalmologists and compounding pharmacies performing anti-VEGF injections for wet-AMD, diabetic macular edema, and retinal vein occlusion; the company also identifies mRNA-based vaccines and gene & cell therapy as secondary application segments. The technology is differentiated by peer-reviewed performance data showing +0.70% dosing accuracy (vs. +9.42-19.41% for standard syringes), residual volume of ~1.4μL (vs. 24.86-51.97μL), and dramatically lower silicone oil particle release after agitation.

The company operates a direct enterprise field sales model targeting healthcare facilities and compounding pharmacies, supported by eight regional vice presidents covering North America, Western Europe, Northern Europe, DACH, LATAM, APAC Southeast Asia, Middle East & Africa, and Central Eastern Europe / ANZ / South Asia, plus a dedicated US website. Revenue is generated exclusively through hardware sales of proprietary CE-marked devices; pricing is not publicly disclosed and quotes are issued on request. SJJ Solutions is a privately held, family-controlled B.V. (Dutch Chamber of Commerce registration 71377352), with multiple Schootstra family members holding CEO, CIO, and Principal Engineer roles; the only disclosed external capital is a 2023 Kansen voor West III EU subsidy funding R&D for the ZR-concept 2.0 next-generation platform. Key commercial relationships include an industry development agreement with Inven2 (the commercialization arm of Oslo University Hospital and the South-Eastern Norway Regional Health Authority) and a 2021 collaboration with the Dutch RIVM during the COVID-19 vaccination campaign.

Name

SJJ Solutions

Legal name

SJJ Solutions B.V.

Website

https://sjjsolutions.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

SJJ Solutions is a Dutch medical device company that designs and sells the Zero Residual™ integrated silicone oil-free syringe system for precision small-volume drug delivery, primarily serving ophthalmologists and compounding pharmacies performing intravitreal anti-VEGF injections.

Ownership category

akta.pro rank

Product category

Ophthalmic Medical Devices

NAICS

Ophthalmic Goods Manufacturing (339115), Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841), Ophthalmic Goods (3851)

akta.pro primary industry

Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL)

akta.pro secondary industry

Prefilled Syringes & Safety Syringes (HLAHAIAA)

Keywords

• Ophthalmic medical devices
• Intravitreal injection syringes
• Silicone oil-free syringes
• Small volume drug delivery
• Medical device manufacturing

Headquarters

HQ city

Den Haag

HQ country

Netherlands

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: SJJ Solutions generates revenue through the sale of proprietary medical devices including syringes, needles, bubble adapters, filter needles, and caps. Products are sold directly to healthcare facilities, compounding pharmacies, and ophthalmology practices. The company serves multiple markets including ophthalmic, mRNA-based vaccines, and gene & cell therapy.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

SJJ Solutions designs, develops, manufactures, and sells the Zero Residual™ product line — silicone oil-free syringes, needles, bubble adapters, Luer Lock caps, and silicone oil-free filter needles — for small volume drug delivery in ophthalmic (intravitreal) injections. Products are CE MDR-approved and ISO 9001 certified, sold directly to healthcare facilities, eye clinics, compounding pharmacies, and ophthalmic specialists worldwide.

Product overview

SJJ Solutions offers the Zero Residual™ product line—a modular system of medical devices for small volume dosing in ophthalmic applications. The core offering centers on the Zero Residual™ 0.2ml silicone oil-free syringe, complemented by specialized needles (30G, 33G in various lengths), the Bubble Adapter for air-free prefilling, Luer Lock cap, and silicone oil-free filter needle. An additional 0.3ml low silicone syringe variant extends the portfolio. All components are designed for interoperability, targeting anti-VEGF injections for wet-AMD and DME treatments, as well as mRNA-based vaccines and gene & cell therapy applications.

Differentiator

Problem solved

Functional benefit

Brands

• Zero Residual™: The company's core product concept and brand for silicone oil-free syringes and related medical devices designed for small volume dosing in ophthalmic and other medical applications.

Products and services

• Zero Residual™ 0.2ml SiO-free Syringe The first CE-approved silicone oil-free syringe designed for small volume dosing, specifically tailored for intravitreal injections. Features a 0.2mL capacity with Luer Lock connection, 2.48mm inner diameter, and 11mm stroke length for precise dosing control.
• Zero Residual™ Needles Injection needles designed to fit exactly on all Zero Residual™ syringes, available in 30G and 33G gauges with 9mm and 13mm lengths. Each batch is tested for sharpness before release.
• Zero Residual™ Bubble Adapter CE MDR approved adapter that enables air-free prefilling of syringes. Solves the common problem of filling syringes with filter needles while preventing air bubble introduction and reducing silicone oil contamination risk.
• Zero Residual™ Cap Luer Lock cap allowing air-free prefilling of Zero Residual™ syringes. The design ensures firm seal and closure integrity of prefilled syringes.
• Zero Residual™ SiO-free Filter Needle The world's first commercially available silicone oil-free filter needle. Eliminates potential silicone oil risk when using filter needles with Zero Residual™ products, completing the silicone oil-free path from vial to patient.
• Zero Residual™ 0.3ml Low Silicone Syringes Low silicone content syringes with 0.3ml capacity designed for small volume injections, complementing the zero residual product line.

Quantifiable outcome

• Zero Residual Silicone Oil-free syringe shows +0.70% dosing accuracy compared to standard syringes ranging from +9.42% to +19.41% deviation
• +4 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Two partnerships are on record, tiered core.

• Oslo University HospitalcoreStrategic or Co-development PartnerOslo University Hospital is a highly specialized hospital with regional and local responsibilities and national missions across multiple competency centers. The hospital collaborated with SJJ Solutions on research and development of the Zero Residual syringe concept, contributing clinical expertise and validation capabilities. Collaborative agreements exist related to the development of syringes by SJJ Solutions.
• Inven2coreStrategic or Co-development PartnerInven2 is responsible for evaluating and commercializing innovative research from the University of Oslo, Oslo University Hospital, and health trusts under the South-Eastern Norway Regional Health Authority. SJJ Solutions signed an industry development agreement with Inven2 for collaborative product development and commercialization.

Scale indicators3 records

Recent moves12 records

Expansion highlights6 records

Broad incumbents

• B. Braun Melsungen: German medical device and pharmaceutical company with an extensive syringe and infusion therapy portfolio. Its Integra and Omnifix syringe lines are used across European hospital pharmacies and could be repositioned with low-residual designs.
• Smiths Medical (ICU Medical): Specialty medical device company with syringe pumps, injection devices, and safety needles serving hospital and ophthalmology markets. Comparable in scale to a potential acquirer and a meaningful channel for ophthalmic injection products.
• Becton, Dickinson and Company (BD): Global medical technology leader with a large syringe and drug delivery portfolio including 1ml low-dead-volume syringes used by compounding pharmacies for intravitreal injections. BD is the dominant incumbent whose products SJJ displaces in ophthalmology workflows.
• Terumo Corporation: Japanese medical device manufacturer with a substantial syringe and injection device business serving hospitals globally. Terumo has the R&D scale and global distribution to enter the silicone oil-free ophthalmic syringe segment if market demand is proven.
• West Pharmaceutical Services: Leader in elastomer components, syringe plungers, and drug containment/delivery systems serving injectable biologics. West works closely with anti-VEGF manufacturers on packaging and could integrate silicone oil-free components into its offering.

Regional players

• Gerresheimer AG: European pharmaceutical packaging and specialty glass manufacturer producing primary packaging for injectables including syringes. Adjacent to SJJ's category with deep European manufacturing footprint and biopharma customer relationships.

Direct peers

• Hamilton Company: Manufacturer of precision syringes including specialty low-volume models used in analytical and medical applications. Hamilton's glass syringes are widely used in ophthalmic compounding, making it one of the most direct product competitors to SJJ's Zero Residual™ system.
• Nipro Corporation: Japanese medical device manufacturer with a comprehensive syringe and needle product line distributed globally. Nipro's specialty syringes serve ophthalmology and diabetes markets, positioning it as a direct functional peer.

Emerging players

• Stevanato Group: Italian drug containment and delivery solutions provider serving biologics manufacturers with syringes, vials, and devices. Comparable in their focus on high-value injectable packaging and their growing presence in the ophthalmic biologics supply chain.
• Owen Mumford: UK-based specialty medical device manufacturer of injection and blood sampling devices. Comparable in being a mid-sized specialty device company with proprietary delivery technology and direct healthcare provider relationships.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks4 records

Key highlights7 records

Customer concentration

• Xx.com/SolutionsSjj
• LinkedInlinkedin.com/company/sjj-solutions-bv

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SJJ Solutions